Cost-effectiveness of including salmeterol in asthma therapy in a primary care setting in Japan

Yakugaku Zasshi

Volumn 126, Issue 1, 2006, Pages 51-59

  Miyagawa, Takehiko ^a   Arakawa, Ichiro ^b   Shiragami, Makoto ^b   Nishimura, Shuzo ^c  

^a Miyagawa Clinic   (Japan)

^b NIHON UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Asthma; Cost effectiveness; Pharmacoeconomics; Salmeterol

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; SALMETEROL; THEOPHYLLINE;

ADULT; ARTICLE; ASTHMA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HUMAN; INFORMED CONSENT; JAPAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PRACTICE GUIDELINES; PRIMARY HEALTH CARE; RETROSPECTIVE STUDIES;

EID: 29944446080     PISSN: 00316903     EISSN: 13475231     Source Type: Journal    
DOI: 10.1248/yakushi.126.51     Document Type: Article

References (23)

1. Juniper E. F., Jenkins C., Price M. J., James M. H., Am. J. Respir. Med., 1(6), 435-440 (2002).
2. Miyagawa T., Med. Drug J., 39, 2323-2328 (2003) (in Japanese).
3. Miyagawa T., Nishimura S., Aller. Inter., 54, 345-349 (2005).
4. NHLBI., Global Strategy for Asthma Management and Prevention. 〈http://www.ginasthma.com〉, 2002.
5. Japan Clinical Evidence Committee Edit, Asthma, Nikkei, 1273-1274 (2002) (in Japanese).
6. Shrewsbury S., Pyke S., Britton M., BMJ, 320, 1368-1372 (2000).
7. Price D. B., Maier W. C., Price M. J., McQuay L. J., Am. J. Respir. Crit. Care. Med., 161(3): A197 (2000).
8. Edin H. M., Lange M. L., Vandermeer A. K., House K. W., Shah T. P., J. Allergy Clin. Immunol., 109(1), S241 (2002a).
9. Lyseng-Williamson K. A., Plosker G. L., Pharmacoeconomics 21, 951-989 (2003).
10. Drummond M., eds. by Drummond M., O'Brien B., Stoddart G.L., "Methods for the Economic Evaluation of Health Care Programmes, 2nd ed., eds. by Oxford University Press, New York, 1997, pp. 68-74.
11. Consumer Price Index. Statistics Bureau, Ministry of Public Management, Home Affairs, Posts and Telecommunications (in Japanese). 〈http://www.stat. co.jp〉.
12. Ministry of Education, Culture, Sports, Science, and Technology (MECSST), Ministry of Health, Labour, and Welfare (MHLW). Ethical guidelines for epidemiological research (English version). 〈http://www.niph.go.jp/wadai/ ekigakurinri/index.htm〉. 17 June 2002.
13. MHLW Statistics database. Wage structure survey for 2002 〈http://wwwdbtk.mhlw.go.jp/toukei/index.html〉. (in Japanese).
14. Adachi M., Morikawa A., Ishihara K., Allergy, 51, 411-420 (2002) (in Japanese).
15. Morita M., Nagakura T., Suguro H., et al. Aller. Immunol., 12: 786-799 (2005).
16. MHLW Statistics database. Medical expenditure survey for 2002 〈http://wwwdbtk.mhlw.go.jp/toukei/index.html〉. (in Japanese).
17. MHLW Statistics database. Vital statistics of Japan 2002 〈http://wwwdbtk.mhlw.go.jp/toukei/index.html〉. (in Japanese).
18. UK national statistics online. 〈http://www.statistics.gov.uk/ downloads/theme_health/Dh2_297DH2No29.pdf〉
19. Kochanek K. D., Murohy S. L., Anderson R. N., et al. National Vital Statistics Report, 53 (5), 2004-1012. 〈http://www.cdc.gov/nchs/data/nvsr/ nvsr53/nvsr53_05.pdf〉.
20. Australian Bureau of Statistics. Causes of Death 2002. 〈http://www.abs.gov.au/〉.
21. Jenkins C., Wookcock A.J., Saarelainen P., et al. Respir. Med., 94: 715-723 (2000).
22. Agency for Health Care Policy and Research (AHCPR). Hierarchy of study designs 〈http://www/ahcpr.gov〉.
23. Anonymous, "Validity and Bias," eds. by Greenberg R. S., Daniels S. R., Flanders W. D., Medical Epidemiology, 3rd ed. McGraw-Hill, New York, 2001, p. 144.